Alivus Life Sciences
ALIVUS · Pharma > Pharmaceuticals & Drugs · Chairman: Glenn Saldanha · MD: Yasir Rawjee · Listing date: Aug. 7, 2021 · Employees: 1537 · Mumbai · http://www.glenmarklifesciences.com

Stock Price vs Company Growth
1d
1.1%
1w
5.0%
1m
3.6%
3m
33.6%
6m
46.5%
1y
49.4%
5y
18.6%
all
15.7%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,371 1.1%
1,005
1,490
Company Overview

Sales
2,590 Cr
Growth: 6.8%
Profit after Tax
603 Cr
Growth: 6.8%
Mid Cap
16,831 Cr
P/E: 27.9x
Industry P/E: 34.2x
Fundamentals

Sales (Cr) ₹ 2,590
Growth 6.8%
EBITDA 32.3%
P/S 6.5x
Dividend 0.5%
P/E 27.9x
Book Value ₹ 284
PEG Ratio 4.1x
ROE 18.4%
P/B 4.8x
Shareholding Pattern

Institutions
Promoters
Others
Increase    Decrease    No change
Company Profile Detailed

The company is in the business of making high-quality drugs by unlocking the possibilities of science.Awards, accreditations and recognitions2015: Ankleshwar plant received ISO 14001:2015 certifying the management system of manufacturing facility.2016: Dahej plant received ISO 14001:2015 certifying the management system of manufacturing facility.2016: Ankleshwar plant received BS OHSAS 18001:2017 certifying the management system of the manufacturing facility.
Investors (7)
Followers (2)